Gritstone bio to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – GRTS
The recorded move for GRTS in the trading session of this news was -2.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences:
6th Annual Evercore ISI HealthCONx Conference (Fireside Chat)
Presentation Date and Time: Wednesday, November 29, 2023 at 10:00am ET
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: Miami, FL
35th Annual Piper Sandler Healthcare Conference (Fireside Chat)
Presentation Date and Time: Thursday, November 30, 2023 at 10:00am ET
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: New York, NY
First Annual Goldman Sachs Catalyst Clinic (Fireside Chat)
Presentation Date and Time: Tuesday, December 5 at 11:00am ET
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: Virtual
Live webcasts of the fireside chats will be available via https://ir.gritstonebio.com/investors/events. Archived replays will be accessible for 30 days following each event.
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone Contacts
Investors:
George E. MacDougall
Gritstone bio, Inc.
ir@gritstone.com
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com